{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:14:04Z","timestamp":1789820044968,"version":"4.0.1"},"reference-count":10,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2023,2,14]]},"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1183\/23120541.00695-2022","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T16:10:27Z","timestamp":1679587827000},"page":"00695-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Benefit\u2212risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis"],"prefix":"10.1183","volume":"9","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Metersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Feliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Teper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2024101711541486000_9.3.00695-2022.1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101711541486000_9.3.00695-2022.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra012519"},{"key":"2024101711541486000_9.3.00695-2022.3","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101711541486000_9.3.00695-2022.4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711541486000_9.3.00695-2022.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2024101711541486000_9.3.00695-2022.6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cpt.1053","article-title":"Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects","volume":"104","author":"Palm\u00e9r","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024101711541486000_9.3.00695-2022.7","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","article-title":"Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986)","volume":"59","author":"Doyle","year":"2016","journal-title":"J Med Chem"},{"key":"2024101711541486000_9.3.00695-2022.8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2021.02.027","article-title":"Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder","volume":"285","author":"Arnaud","year":"2021","journal-title":"J Affect Disord"},{"key":"2024101711541486000_9.3.00695-2022.9","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12142"},{"key":"2024101711541486000_9.3.00695-2022.10","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0167-9"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00695-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:24:27Z","timestamp":1740374667000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00695-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,2]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1183\/23120541.00695-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00695-2022","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}